
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| VIRA-A | Parkedale Pharmaceuticals | N-050486 DISCN | 1982-01-01 | 1 products |
| VIRA-A | Parkedale Pharmaceuticals | N-050523 DISCN | 1982-01-01 | 1 products |

Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hepatitis | D006505 | — | K75.9 | 127 | 214 | 124 | 93 | 191 | 705 |
| Hiv infections | D015658 | EFO_0000764 | B20 | 163 | 145 | 97 | 58 | 163 | 602 |
| Hepatitis a | D006506 | EFO_0007305 | B15 | 101 | 182 | 100 | 85 | 152 | 582 |
| Human influenza | D007251 | EFO_0007328 | J11.1 | 143 | 184 | 123 | 70 | 102 | 581 |
| Hepatitis c | D006526 | — | B19.2 | 99 | 178 | 128 | 65 | 138 | 571 |
| Infections | D007239 | EFO_0000544 | — | 122 | 157 | 86 | 22 | 168 | 515 |
| Covid-19 | D000086382 | — | U07.1 | 62 | 110 | 79 | 31 | 189 | 433 |
| Virus diseases | D014777 | — | B34 | 127 | 126 | 59 | 15 | 100 | 401 |
| Hepatitis b | D006509 | — | — | 66 | 110 | 64 | 42 | 93 | 351 |
| Myeloid leukemia acute | D015470 | — | C92.0 | 144 | 180 | 43 | 3 | 14 | 327 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Precursor cell lymphoblastic leukemia-lymphoma | D054198 | — | C91.0 | 63 | 93 | 29 | — | 11 | 174 |
| Myelodysplastic syndromes | D009190 | — | D46 | 64 | 101 | 10 | — | 9 | 154 |
| Recurrence | D012008 | — | — | 50 | 58 | 8 | — | 11 | 107 |
| Dengue | D003715 | — | A90 | 45 | 28 | 11 | — | 14 | 96 |
| Hodgkin disease | D006689 | — | C81 | 26 | 42 | 6 | — | 10 | 71 |
| Lymphoid leukemia | D007945 | — | C91 | 31 | 40 | 9 | — | 2 | 70 |
| Preleukemia | D011289 | — | — | 28 | 48 | 3 | — | 2 | 65 |
| B-cell chronic lymphocytic leukemia | D015451 | — | C91.1 | 23 | 39 | 5 | — | 7 | 64 |
| Melanoma | D008545 | — | — | 39 | 28 | 3 | — | 3 | 63 |
| Bcr-abl positive chronic myelogenous leukemia | D015464 | EFO_0000340 | — | 16 | 42 | 4 | — | 5 | 62 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Squamous cell carcinoma | D002294 | — | — | 20 | 20 | — | — | 8 | 44 |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 33 | 9 | — | — | 4 | 41 |
| T-cell lymphoma | D016399 | — | — | 12 | 22 | — | — | 4 | 32 |
| Lymphoproliferative disorders | D008232 | Orphanet_2442 | D47.9 | 15 | 17 | — | — | 2 | 30 |
| Zika virus infection | D000071243 | — | A92.5 | 15 | 2 | — | — | 13 | 30 |
| B-cell lymphoma marginal zone | D018442 | — | C88.4 | 10 | 18 | — | — | 5 | 29 |
| Adenoviridae infections | D000257 | EFO_1001259 | B34.0 | 22 | 11 | — | — | 5 | 29 |
| Prostatic neoplasms | D011471 | — | C61 | 13 | 17 | — | — | 2 | 27 |
| Glioma | D005910 | EFO_0000520 | — | 19 | 9 | — | — | 2 | 25 |
| Lung neoplasms | D008175 | — | C34.90 | 19 | 6 | — | — | 3 | 24 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Dermatitis | D003872 | — | L30.9 | 1 | — | — | — | 6 | 7 |
| Atopic dermatitis | D003876 | EFO_0000274 | L20 | 1 | — | — | — | 6 | 7 |
| Oligodendroglioma | D009837 | EFO_0000631 | — | 5 | — | — | — | 1 | 6 |
| Emergencies | D004630 | — | — | 2 | — | — | — | 4 | 6 |
| Suicide | D013405 | — | — | 2 | — | — | — | 3 | 5 |
| Smoking cessation | D016540 | EFO_0004319 | — | 1 | — | — | — | 4 | 5 |
| Inflammatory bowel diseases | D015212 | EFO_0003767 | — | 1 | — | — | — | 4 | 5 |
| Germ cell and embryonal neoplasms | D009373 | — | — | 4 | — | — | — | — | 4 |
| Medulloblastoma | D008527 | — | — | 4 | — | — | — | — | 4 |
| Hiv seronegativity | D018023 | — | — | 4 | — | — | — | — | 4 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Anxiety | D001007 | EFO_0005230 | F41.1 | — | — | — | — | 6 | 6 |
| Rhinovirus | D012229 | — | — | — | — | — | — | 6 | 6 |
| Community-acquired pneumonia | D000098968 | — | — | — | — | — | — | 5 | 5 |
| Sleep initiation and maintenance disorders | D007319 | — | F51.01 | — | — | — | — | 5 | 5 |
| Coronary artery disease | D003324 | — | I25.1 | — | — | — | — | 5 | 5 |
| Recreational drug use | D000084783 | — | — | — | — | — | — | 5 | 5 |
| Critical illness | D016638 | — | — | — | — | — | — | 5 | 5 |
| Neck pain | D019547 | — | M54.2 | — | — | — | — | 4 | 4 |
| Anxiety disorders | D001008 | EFO_0006788 | F41.1 | — | — | — | — | 4 | 4 |
| Gonorrhea | D006069 | DOID_7551 | A54 | — | — | — | — | 4 | 4 |
| Drug common name | Vidarabine |
| INN | vidarabine |
| Description | Adenine arabinoside is a purine nucleoside in which adenine is attached to arabinofuranose via a beta-N(9)-glycosidic bond. It has a role as an antineoplastic agent, a bacterial metabolite and a nucleoside antibiotic. It is a purine nucleoside and a beta-D-arabinoside. It is functionally related to an adenine. |
| Classification | Small molecule |
| Drug class | antineoplastics (arabinofuranosyl derivatives) |
| Image (chem structure or protein) | ![]() |
| Structure (InChI/SMILES or Protein Sequence) | Nc1ncnc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O |
| PDB | — |
| CAS-ID | 5536-17-4 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1090 |
| ChEBI ID | 45327 |
| PubChem CID | 21704 |
| DrugBank | DB00194 |
| UNII ID | 3XQD2MEW34 (ChemIDplus, GSRS) |






